Average Co-Inventor Count = 7.70
ph-index = 4
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Deutsches Krebsforschungszentrum (4 from 155 patents)
2. Ruprecht-karls-universitat Heidelberg (4 from 60 patents)
3. Novartis Ag (2 from 3,923 patents)
4. Ruprecht-Karls-universitÄt (7 patents)
6 patents:
1. 11951190 - Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer
2. 11931430 - Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
3. 11045564 - Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
4. 10471160 - Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
5. 10398791 - Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
6. 10016519 - 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer